How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe
How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe
复制标题
DOI：
10.1007/s10461-017-1685-x
复制
发表时间：
2018-03-01
影响因子：
4.4
通讯作者：
Mensch, Barbara
中科院分区：
文献类型：
--
作者：
Musara, Petina;Montgomery, Elizabeth T.;Mensch, Barbara
研究产品使用的准确估计对于理解和解决HIV预防试验中的依从性挑战至关重要。VOICE试验暴露了自我报告的依从性和药物检测之间的显著差距。VOICE-D定性研究旨在更好地了解VOICE期间的不依从性，并分2个阶段进行：向参与者提供药物检测结果之前（阶段1）和之后（阶段2）。对参加这两个阶段的44名妇女的成绩单进行了分析，以了解药物检测数据对产品使用叙述的影响。36名妇女在第1阶段报告了高依从性，但在第2阶段承认未使用，3名妇女在两个阶段都报告了高依从性（与其药物检测结果相反），5名妇女在两个阶段和药物结果中都有一致的反应。提出客观的使用措施可能有助于更准确的产品使用报告，并应在未来的预防试验中进行评估。
Accurate estimates of study product use are critical to understanding and addressing adherence challenges in HIV prevention trials. The VOICE trial exposed a significant gap between self-reported adherence and drug detection. The VOICE-D qualitative study was designed to better understand non-adherence during VOICE, and was conducted in 2 stages: before (stage 1) and after (stage 2) drug detection results were provided to participants. Transcripts from 44 women who participated in both stages were analysed to understand the effect of presenting drug detection data on narratives of product use. Thirty-six women reported high adherence in stage 1, yet admitted non-use in stage 2, three reported high adherence in both stages (contrary to their drug detection results) and five had consistent responses across both stages and drug results. Presenting objective measures of use may facilitate more accurate product use reporting and should be evaluated in future prevention trials.